DE69819514D1 - Verwendung von physiologisch verträglichen vanadiumverbindungen, salzen und komplexen - Google Patents

Verwendung von physiologisch verträglichen vanadiumverbindungen, salzen und komplexen

Info

Publication number
DE69819514D1
DE69819514D1 DE69819514T DE69819514T DE69819514D1 DE 69819514 D1 DE69819514 D1 DE 69819514D1 DE 69819514 T DE69819514 T DE 69819514T DE 69819514 T DE69819514 T DE 69819514T DE 69819514 D1 DE69819514 D1 DE 69819514D1
Authority
DE
Germany
Prior art keywords
complexes
salts
physiologically compatible
vanadium compounds
surrounding tissue
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
DE69819514T
Other languages
English (en)
Other versions
DE69819514T2 (de
Inventor
Conradus Ghosal Gho
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
CFM PHARMA HOLDING B.V., ALMERE, NL
Original Assignee
GHO ST HOLDING BV
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by GHO ST HOLDING BV filed Critical GHO ST HOLDING BV
Publication of DE69819514D1 publication Critical patent/DE69819514D1/de
Application granted granted Critical
Publication of DE69819514T2 publication Critical patent/DE69819514T2/de
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K33/00—Medicinal preparations containing inorganic active ingredients
    • A61K33/24—Heavy metals; Compounds thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P41/00—Drugs used in surgical methods, e.g. surgery adjuvants for preventing adhesion or for vitreum substitution
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
DE69819514T 1997-07-29 1998-07-29 Verwendung von physiologisch verträglichen vanadiumverbindungen, salzen und komplexen Expired - Lifetime DE69819514T2 (de)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
NL1006681A NL1006681C2 (nl) 1997-07-29 1997-07-29 Toepassing van fysiologisch acceptabele vanadiumverbindingen, -zouten en -complexen.
NL1006681 1997-07-29
PCT/NL1998/000431 WO1999006056A1 (en) 1997-07-29 1998-07-29 Use of physiologically acceptable vanadium compounds, salts and complexes

Publications (2)

Publication Number Publication Date
DE69819514D1 true DE69819514D1 (de) 2003-12-11
DE69819514T2 DE69819514T2 (de) 2004-09-23

Family

ID=19765422

Family Applications (1)

Application Number Title Priority Date Filing Date
DE69819514T Expired - Lifetime DE69819514T2 (de) 1997-07-29 1998-07-29 Verwendung von physiologisch verträglichen vanadiumverbindungen, salzen und komplexen

Country Status (22)

Country Link
US (2) US6579540B1 (de)
EP (1) EP1001792B1 (de)
JP (1) JP2001511454A (de)
CN (1) CN1104244C (de)
AT (1) ATE253373T1 (de)
AU (1) AU738701B2 (de)
BR (1) BR9811298A (de)
CA (1) CA2298645C (de)
CZ (1) CZ299716B6 (de)
DE (1) DE69819514T2 (de)
DK (1) DK1001792T3 (de)
EA (1) EA002574B1 (de)
ES (1) ES2207851T3 (de)
ID (1) ID24870A (de)
IL (2) IL134259A0 (de)
NL (1) NL1006681C2 (de)
NO (1) NO20000446L (de)
NZ (1) NZ502613A (de)
PL (1) PL338415A1 (de)
PT (1) PT1001792E (de)
TR (1) TR200000349T2 (de)
WO (1) WO1999006056A1 (de)

Families Citing this family (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
NL1006681C2 (nl) * 1997-07-29 1999-02-08 Gho St Holding Bv Toepassing van fysiologisch acceptabele vanadiumverbindingen, -zouten en -complexen.
US8192994B2 (en) * 1998-02-10 2012-06-05 Angros Lee H Method of applying a biological specimen to an analytic plate
WO2001045716A1 (en) * 1999-12-20 2001-06-28 Gho'st Holding B.V. Pharmaceutical composition comprising a physiologically acceptable vanadium compound, salt or complex and a na+/h+ exchange inhibitor
WO2003041703A2 (en) * 2001-11-16 2003-05-22 Gho Holding B.V. Use of a flavonoid for the treatment of burns
ES2485384T3 (es) 2007-01-31 2014-08-13 Basf Plant Science Gmbh Plantas que tienen rasgos potenciados relacionados con el rendimiento y/o mayor resistencia al estrés abiótico y un procedimiento para fabricar las mismas
ES2542311T3 (es) 2007-05-03 2015-08-04 Basf Plant Science Gmbh Plantas que tienen rasgos potenciados relacionados con el rendimiento y un procedimiento de producción de las mismas
EP2987861A1 (de) 2007-07-20 2016-02-24 BASF Plant Science GmbH Pflanzen mit verbesserten ertragseigenschaften und verfahren zur herstellung davon
AR067748A1 (es) 2007-07-31 2009-10-21 Basf Plant Science Gmbh Plantas que tienen rasgos mejorados relacionados con el rendimiento y un metodo para obtenerlas
MX2010004305A (es) 2007-10-29 2010-04-30 Basf Plant Science Gmbh Plantas que tienen rasgos relacionados con el rendimiento aumentado y un metodo para producirlas.
EP2274431A1 (de) 2008-05-05 2011-01-19 BASF Plant Science GmbH Pflanzen mit verbesserten ertragseigenschaften und verfahren zu ihrer herstellung
US20100078320A1 (en) * 2008-09-26 2010-04-01 Applied Materials, Inc. Microwave plasma containment shield shaping
EP2523672B1 (de) 2010-01-15 2016-07-13 Rutgers, the State University of New Jersey Verwendung von vanadiumverbindungen für beschleunigte knochenheilung
US20140322292A1 (en) 2010-12-10 2014-10-30 Rutgers, The State University Of New Jersey Insulin-mimetics as therapeutic adjuncts for bone regeneration
CA2820297C (en) 2010-12-10 2019-06-25 University Of Medicine And Dentistry Of New Jersey Implantable devices coated with insulin-mimetic agent composites and methods thereof
AU2012226703A1 (en) 2011-03-07 2013-10-17 Cfm Pharma Holding Bv Use of vanadium compounds for maintaining normaglycemia in a mammal
US9931348B2 (en) * 2011-07-06 2018-04-03 Rutgers, The State University Of New Jersey Vanadium compounds as therapeutic adjuncts for cartilage injury and repair
PL231079B1 (pl) 2012-11-07 2019-01-31 Univ Jagiellonski Kompleksy wanadu z hydrazydohydrazonami, preparaty farmaceutyczne oraz zastosowanie kompleksów wanadu z hydrazydohydrazonami
NL2019605B1 (en) * 2017-09-22 2019-03-28 Cfm Pharma Holding B V Vanadyl and vanadate for use in reducing stress-induced metabolic derangement

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU5448490A (en) * 1989-04-24 1990-11-16 Board Of Regents, The University Of Texas System Compositions and processes for improving the cosmetic appearance, growths or healing characteristics of tissue
US5565491A (en) * 1994-01-31 1996-10-15 Bristol-Myers Squibb Company Use of phosphotyrosine phospatase inhibitors for controlling cellular proliferation
FR2729957B1 (fr) * 1995-01-31 1997-12-05 Maurel Sante Complexes organometalliques a base de sitosterols et d'acylglycerols et compositions pharmaceutiques et produits dietetiques en contenant.
NL1006681C2 (nl) * 1997-07-29 1999-02-08 Gho St Holding Bv Toepassing van fysiologisch acceptabele vanadiumverbindingen, -zouten en -complexen.

Also Published As

Publication number Publication date
NO20000446L (no) 2000-03-24
ATE253373T1 (de) 2003-11-15
TR200000349T2 (tr) 2000-09-21
WO1999006056A1 (en) 1999-02-11
PT1001792E (pt) 2004-03-31
PL338415A1 (en) 2000-11-06
US6579540B1 (en) 2003-06-17
CZ2000326A3 (cs) 2000-07-12
EP1001792B1 (de) 2003-11-05
IL134259A (en) 2010-02-17
NL1006681C2 (nl) 1999-02-08
NZ502613A (en) 2001-08-31
EA200000176A1 (ru) 2000-10-30
CA2298645C (en) 2004-05-18
ID24870A (id) 2000-08-31
EP1001792A1 (de) 2000-05-24
AU8650598A (en) 1999-02-22
JP2001511454A (ja) 2001-08-14
US20030211170A1 (en) 2003-11-13
CA2298645A1 (en) 1999-02-11
AU738701B2 (en) 2001-09-27
CN1270525A (zh) 2000-10-18
DE69819514T2 (de) 2004-09-23
ES2207851T3 (es) 2004-06-01
EA002574B1 (ru) 2002-06-27
NO20000446D0 (no) 2000-01-28
BR9811298A (pt) 2000-08-29
IL134259A0 (en) 2001-04-30
CZ299716B6 (cs) 2008-10-29
DK1001792T3 (da) 2004-01-19
CN1104244C (zh) 2003-04-02

Similar Documents

Publication Publication Date Title
DE69819514D1 (de) Verwendung von physiologisch verträglichen vanadiumverbindungen, salzen und komplexen
UA56989C2 (uk) ФІЗІОЛОГІЧНО АКТИВНИЙ ПЕГ-КОН'ЮГАТ <font face="Symbol">a</font>-ІНТЕРФЕРОНУ, СПОСІБ ЙОГО ОДЕРЖАННЯ, ФАРМАЦЕВТИЧНА КОМПОЗИЦІЯ НА ЙОГО ОСНОВІ ТА СПОСІБ ЛІКУВАННЯ АБО ПРОФІЛАКТИКИ ІМУНОМОДУЛЯТОРНИХ ЗАХВОРЮВАНЬ
TR200000129T2 (tr) Yepyeni spiroazabisiklik heterosiklik bileşikler.
WO2003009838A1 (fr) Utilisation de composes de stilbene dans la preparation de medicaments pour le traitement ou la prevention du diabete et des maladies associees au retrovirus
DE69529670T2 (de) Oxazolidinon derivate und diese enthaltende pharmazeutische zusammensetzungen
EP0509317A3 (en) Use of droloxifene in the treatment of bone diseases
ATE211384T1 (de) Verwendung von adenosinantagonisten zur vorbeugung und behandlung von pankreatitis und ulcera
SE9802208D0 (sv) Novel compounds
ES2160643T3 (es) Composiciones que contienen g-csf y proteina de union al tnf.
ATE289204T1 (de) Arzneimittel zur vorbeugung / behandlung / inhibierung des fortschritts für einfache oder preproliferative retinopathie
CA2289017A1 (en) The use of a nitroxide or a prodrug thereof in the prophylactic and therapeutic treatment of cancer
SE9802209D0 (sv) Novel compounds
WO2001016096A3 (de) Verwendung von bissulfonamiden zur herstellung von medikamenten zur prophylaxe oder behandlung von hyperlipidämie
PL339073A1 (en) Derivatives of benzoxazine and benzothiazine and their application in therapeutic agents
ES2065855A1 (es) Procedimiento para la preparacion de nuevos derivados desoxiazafosfolipidicos con accion inhibidora de la fosfolipasa a2, nuevos derivados desoxiazafosfolipidicos obtenidos y utilizacion de los mismos.
TR200201654T2 (tr) Benzamidin türevleri.
TR200200111T2 (tr) Neoplazmalar için terapötik ve profilaktik maddeler
GR1004434B (el) Χρησηατουαdiclofenacαhααποδεκτωνααλατωνααυτουαγιαατηνααντιμετωπισηατωναεγκαυματων
ES2190499T3 (es) Uso de antagonistas de bradiquinina para la preparacion de medicamentos para el tratamiento y la prevencion de la enfermedad de alzheimer.
DE69614508T2 (de) Thiol derivate mit metallopeptidase inhibierender aktivitat
ATE464051T1 (de) Kombination aus levosimendan und einer kalziumquelle zur behandlung von herzinsuffizienz
WO2001045717A3 (en) Pharmaceutical composition comprising a vanadium compound and at least a component selected from a na+/h+ exchanger, cyclo-oxygenase inhibitors and caspase inhibitors
WO2000002578A8 (fr) Remedes contre les maladies liees a l'apoptose
UA12937A (uk) Засіб для локальhого лікуваhhя гhійhо-запальhих раh та опіків, іhфіковаhих стафілококом

Legal Events

Date Code Title Description
8364 No opposition during term of opposition
8327 Change in the person/name/address of the patent owner

Owner name: CFM PHARMA HOLDING B.V., ALMERE, NL